1. Home
  2. CMTG vs AKBA Comparison

CMTG vs AKBA Comparison

Compare CMTG & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Claros Mortgage Trust Inc.

CMTG

Claros Mortgage Trust Inc.

HOLD

Current Price

$1.55

Market Cap

256.8M

Sector

Real Estate

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.45

Market Cap

248.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMTG
AKBA
Founded
2015
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
256.8M
248.3M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
CMTG
AKBA
Price
$1.55
$0.45
Analyst Decision
Sell
Buy
Analyst Count
6
6
Target Price
$1.87
★ $3.00
AVG Volume (30 Days)
1.9M
★ 8.7M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 93.94
EPS
N/A
★ N/A
Revenue
★ $187,828,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.09
$0.36
52 Week High
$3.62
$1.75

Technical Indicators

Market Signals
Indicator
CMTG
AKBA
Relative Strength Index (RSI) 55.77 35.11
Support Level $1.44 $0.36
Resistance Level $1.65 $1.54
Average True Range (ATR) 0.13 0.07
MACD 0.03 -0.01
Stochastic Oscillator 50.00 19.62

Price Performance

Historical Comparison
CMTG
AKBA

About CMTG Claros Mortgage Trust Inc.

Claros Mortgage Trust Inc is a real estate investment trust. The company is focused mainly on creating a diversified portfolio of income-producing loans collateralized by institutional-quality commercial real estate.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: